Sharpe ratio
0.60Return earned for the risk taken.
Moderate
Moderate risk-adjusted returns. The reward for risk has been average.
+26.27%1Y Absolute Return
-0.31%1D
Loading NAV history…
Past performance is not an indicator of future returns.
Returns calculator comparison
Compare an illustrative investment outcome across return assumptions.
| Asset | Projected corpus | Total invested | Gain | Annual return |
|---|---|---|---|---|
| PGIM India Healthcare Fund - Direct Plan - Growth OptionFund 1Y annualised return · 5Y history unavailable | ₹14,47,736 | ₹7,32,612 | ₹7,15,124 | +26.27% |
| EPFIllustrative annual assumption | ₹8,95,132 | ₹7,32,612 | ₹1,62,520 | +8.25% |
| Residential propertyIllustrative annual assumption | ₹8,67,662 | ₹7,32,612 | ₹1,35,050 | +7.00% |
| PPFIllustrative annual assumption | ₹8,69,819 | ₹7,32,612 | ₹1,37,207 | +7.10% |
| Bank fixed depositIllustrative annual assumption | ₹8,56,981 | ₹7,32,612 | ₹1,24,369 | +6.50% |
| GoldIllustrative annual assumption | ₹8,67,662 | ₹7,32,612 | ₹1,35,050 | +7.00% |
| Savings accountIllustrative annual assumption | ₹7,86,827 | ₹7,32,612 | ₹54,215 | +3.00% |
Illustration only. Fund results use the available NAV-derived annualised return and can be negative. Reference rows are assumptions, not current quoted rates or guaranteed returns; property excludes transaction costs, taxes, and liquidity constraints. Mutual fund investments are subject to market risk.
Wealth multiple
₹1 became₹1.14
₹1 Lakh since launch₹1.14 Lakh
Fund age1.9 yrs
Fund information
Scheme code153039
ISININF663L01Z45
BenchmarkBSE Healthcare TRI
CategoryEquity Scheme - Sectoral/ Thematic
Expense ratio0.96%
Exit loadExit load of 0.50%, if redeemed within 90 days.
Minimum SIP₹1,000 SIP
Return comparison
20th / 932 in category| Period | Fund | Benchmark | Category avg |
|---|---|---|---|
| 1M | +184.28% | — | — |
| 3M | +13.12% | — | — |
| 6M | +36.47% | — | — |
| 1Y | +26.27% | — | +4.16% |
| Since Launch | +14.24% | — | — |
Risk-adjusted performance
Every measure is expanded with a plain-language reading of the latest calculated value.
Sortino ratio
0.85Return earned while limiting downside risk.
Moderate
Moderate downside risk-adjusted performance.
Standard deviation
13.11%How much the fund’s returns fluctuate over time.
Moderate volatility
Returns can move up and down noticeably.
Beta
—How closely the fund moves with the market.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Alpha
—Extra return generated above the benchmark.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Treynor ratio
—Return earned for each unit of market risk taken.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Calmar ratio
0.99How well the fund rewarded investors relative to its biggest decline.
Good
Good return relative to the drawdowns experienced.
Information ratio
—How consistently the fund outperformed its benchmark.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Portfolio allocation
Latest disclosed portfolio mix
Asset allocation
Allocation data has not been disclosed.
Market cap allocation
Sector allocation
Equity exposure by sector
Top holdings
10 of 31 disclosed positions
| Holding | Sector | Instrument type | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 10.86% |
| Divi's Laboratories Ltd | Healthcare | Equity | 10.35% |
| Torrent Pharmaceuticals Ltd | Healthcare | Equity | 9.38% |
| Aster DM Healthcare Ltd | Healthcare | Equity | 6.21% |
| Max Healthcare Institute Ltd | Healthcare | Equity | 5.86% |
| Ajanta Pharma Ltd | Healthcare | Equity | 5.2% |
| Mankind Pharma Ltd. | Healthcare | Equity | 4.66% |
| Others CBLO | Unspecified | CBLO | 4.32% |
| Dr. Lal Pathlabs Ltd | Healthcare | Equity | 4.05% |
| Krishna Institute Of Medical Sciences Ltd | Healthcare | Equity | 3.77% |
Fund management
AN
Anandha Padmanabhan Anjeneyan
Since 2024 · Prior to joining PGIM India Asset Management Pvt Ltd, he has worked with Renaissance Investment Managers Private Limited, Canara Robeco Asset Management Company Limited.
Mr. Anjeneyan is a B. Com, ACA, CFA, FRM
VI
Vivek Sharma
Since 2024 · Prior to joining PGIM India Asset Management Pvt. Ltd. - Equity Analyst and Asst. Fund Manager, he has worked with ICICI Securities Ltd. - Equity Analyst and JP Morgan Services India Pvt. Ltd.- Associate - Investment Banking.
Mr. Sharma is a PGDM Finance
UT
Utsav Mehta
Since 2024 · Prior to joining PGIM Mutual Fund, he has worked with Edelweiss Asset Management Ltd and Ambit Capital
Mr. Mehta has done B.Com and CFA
PU
Puneet Pal
Since 2024 · Prior to joining PGIM India Mutual Fund, he has worked with BNP Paribas AMC as Head Fixed Income, UTI AMC as Sr. Vice President & Fund Manager & TATA AMC as Fund Manager.
Mr. Pal is a B.Com (H) and MBA from SIBM Pune.
Compare similar funds
No comparable category funds are available yet.
Summary
A very high-risk equity scheme - sectoral/ thematic fund. Losses and swings stayed contained — worst fall -14.4%, volatility 13.1%. Top 10 holdings make up 64% — a handful of stocks can swing returns sharply.
Strengths
- Losses and swings stayed contained — worst fall -14.4%, volatility 13.1%.
- Recovered from its worst fall in 5 months.
- Ranks 20 of 932 in its category over 1 year.
Weaknesses
- Top 10 holdings make up 64% — a handful of stocks can swing returns sharply.
Ideal investor
- Needs a 5–7+ years horizon to ride out its very high risk level.
- Good fit for SIPs — spreading purchases smooths out 13.1% volatility.
Risk drivers
- Top 10 holdings = 64% of the portfolio.
- Healthcare makes up 91% — trouble in that sector hits the whole fund.